TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

Heartflow’s CT-guided PCI matches IVUS outcomes with faster, less invasive procedures.

What the company is saying

Heartflow, Inc. uses this announcement to position itself as the leader in AI-powered coronary artery disease diagnostics, emphasizing robust clinical validation and operational adoption. The company highlights the P4 randomized clinical trial, which enrolled 1,105 patients across 23 centers in the U.S., Europe, and Japan, showing CT-guided PCI is non-inferior to IVUS for one-year clinical outcomes. The messaging stresses greater procedural efficiency, citing a 27% reduction in procedure time and a 12% reduction in contrast use, and more than doubling the use of advanced calcium modification. Heartflow underscores the NAVIGATE-PCI registry, where 70% of treatment plans were modified after using PCI Navigator, with stent length and lesion preparation changes most frequent. The BRAVEHEART registry is used to demonstrate the technology’s preventive potential, with 72% of firefighters showing subclinical plaque and 68% willing to start lipid-lowering therapy after review. The company repeatedly references its FDA clearance, 95% agreement with IVUS, validation in 23,000 patients, and adoption by over 1,800 institutions managing 750,000 patients. Named executives, including Chief Medical Officer Campbell Rogers and principal investigators Carlos Collet and Ziad Ali, lend credibility to the clinical claims. The tone is confident, supported by extensive peer-reviewed evidence and operational metrics.

What the data suggests

The P4 trial’s 1,105-patient data set shows CT-guided PCI achieved a 4.1% 12-month target-vessel failure rate, nearly identical to IVUS at 4.6%, meeting the primary endpoint for non-inferiority. Median procedure time was 46 minutes for CT-guided PCI versus 63 minutes for IVUS, a 17-minute or 27% reduction. Contrast volume was reduced by 12% (150 mL vs. 170 mL). Advanced calcium modification was used in 9.2% of CT-guided cases versus 3.8% for IVUS. In the NAVIGATE-PCI registry of 203 patients, 70% of plans changed after reviewing PCI Navigator, with stent length (41%) and lesion preparation (12%) most affected. The BRAVEHEART registry found 72% of 96 firefighters had subclinical plaque, 16% had severe plaque, 68% were willing to start lipid-lowering therapy, and 93% committed to lifestyle changes after Heartflow analysis. Heartflow Plaque Analysis shows 95% agreement with IVUS and is validated in 23,000 patients over up to 16 years. The technology is adopted by over 1,800 institutions, used for more than 750,000 patients, and powered by a database of over 200 million annotated CTA images. Clinical validation spans over 200 studies and 365,000 patients, and image acceptance rates exceed 97%. The data is comprehensive for clinical and operational performance, but financial metrics such as revenue or profitability are not disclosed.

Analysis

The announcement is highly positive in tone, but the claims are overwhelmingly supported by realised, measurable clinical and operational data. The P4 trial results, registry outcomes, and adoption metrics are all presented with specific numerical evidence, and nearly all key claims are realised rather than forward-looking. Only one claim (regarding meeting or exceeding international standards) is forward-looking or unverifiable from the data provided. There is no evidence of exaggerated narrative or overstatement: the language is proportionate to the scale and specificity of the disclosed results. No large capital outlay or long-dated, uncertain returns are discussed, and the benefits of the technology are already being realised in clinical practice. The absence of financial metrics (revenue, profit, cash flow) means the signal cannot be strong_positive, but the operational and clinical progress is clear and well-supported.

Risk flags

• ●Financial transparency is limited, as the announcement does not disclose revenue, profitability, or cost metrics. This restricts investors’ ability to assess commercial traction or margin sustainability, despite strong operational and clinical adoption.
• ●Clinical adoption, while broad, may face inertia or resistance in markets where IVUS is deeply entrenched or reimbursement for CT-guided PCI is not yet established. The announcement does not address payer or regulatory hurdles in specific geographies.
• ●Regulatory and compliance claims reference meeting or exceeding standards such as HITRUST r2, SOC 2 Type 2, and ISO 13485, but no audit results, certification numbers, or recency are disclosed, making it difficult to verify ongoing compliance.
• ●The technology’s effectiveness is validated in large trials and registries, but real-world outcomes may vary with operator experience, institutional workflow integration, and patient selection, which are not detailed in the release.

Bottom line

Heartflow’s announcement provides strong clinical evidence that its CT-guided PCI planning matches IVUS outcomes while improving efficiency, supported by a 1,105-patient randomized trial and real-world registry data. The operational adoption is significant, with over 1,800 institutions and 750,000 patients, and the technology’s AI foundation is validated by large-scale datasets and high image acceptance rates. The absence of financial disclosures means investors cannot assess revenue growth, profitability, or cost structure, which is a material gap for evaluating commercial momentum. Clinical and operational claims are credible and well-supported, but future updates should include financial metrics to gauge market penetration and sustainability. The most important takeaway is that Heartflow’s technology is already influencing clinical practice at scale, but the investment case would be strengthened by transparent financial reporting.

Announcement summary

(NASDAQ:HTFL) Heartflow, Inc. announced new randomized clinical data at the Transcatheter Cardiovascular Therapeutics (TCT) symposium, demonstrating that CT-guided percutaneous coronary intervention (PCI) matches gold-standard intravascular ultrasound (IVUS) outcomes with greater procedural efficiency. The P4 randomized clinical trial enrolled 1,105 patients across 23 centers in the U.S., Europe, and Japan, and met its primary endpoint by showing CT-guided PCI planning was non-inferior to IVUS for one-year clinical outcomes. CT-guided PCI matched IVUS for the primary endpoint of 12-month target-vessel failure (4.1% vs. 4.6%). CT-guided PCI had a 17-minute shorter median procedure time than IVUS (46 minutes vs. 63 minutes, a 27% reduction). Contrast volume was reduced by approximately 12% in the CT-guided arm (median 150 mL vs. 170 mL). CT-guided PCI more than doubled the use of advanced calcium modification (9.2% vs. 3.8%). The NAVIGATE-PCI registry, involving 203 patients, showed that treatment plans were modified in approximately 70% of cases after physicians reviewed Heartflow PCI Navigator, compared to angiography alone. The most frequent changes included stent length (41%) and lesion preparation technique (12%). Physicians rated their PCI Navigator plans with higher confidence than angiography-based plans. The BRAVEHEART registry evaluated 96 asymptomatic firefighters with at least 10 years of occupational smoke exposure, finding subclinical coronary plaque in 72% and severe total plaque volume (>250 mm³) in 16%. Following review of their CCTA and Heartflow Analysis, 68% of participants were willing to initiate lipid-lowering therapy and 93% committed to lifestyle modifications. Heartflow Plaque Analysis is the only FDA-cleared, AI-powered plaque analysis tool with 95% agreement against IVUS in a prospective, international trial. The Heartflow Plaque Staging framework is validated in 23,000 patients with up to 16 years of follow-up. Heartflow’s technology is supported by more than 625 peer-reviewed publications and has been adopted by over 1,800 institutions globally, managing care for over 750,000 patients worldwide. Heartflow’s AI models are powered by a database of more than 200 million annotated CTA images. Clinical validation includes over 200 studies assessing over 365,000 patients. Heartflow’s coronary CTA image acceptance rates exceed 97%. The company meets or exceeds international standards including HITRUST r2, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.

Disagree with this article?